Kannalife, Inc. has been issued patents in 12 key European territories for its patent known as WO2015/106108A2 and titled, “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”). These territories include Switzerland (CH), Germany (DE), France (FR), the United Kingdom (GB), Ireland (IE), Italy (IT), Spain (ES), Belgium (BE), Sweden (SE), Turkey (TR), the Netherlands (NL), and Denmark (DK). The PCT Patent grants mark the 19th patent that Kannalife has received to date worldwide. Of the 19 patents issued to Kannalife, two are U.S. patents, and 17 are foreign patents.